NOS Life Sciences is committed to the development of solutions to improve the quality of life of patients suffering chronic conditions with highly specific and relevant unmet needs.

Our focus is firstly addressed to Parkinson’s, a progressive neurodegenerative condition affecting 13.1 M patients, causing an economic burden of $120 B, figures that the WHO estimates to double by 2040.

Login

Reset Your Password